Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 3,579 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasms
Interventions: ABI-1968; Drug
Lead sponsor: Antiva Biosciences; Industry
Eligibility: 27 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: San Francisco, California • Orlando, Florida • Chicago, Illinois + 2 more

Conditions: Breast Cancer
Interventions: Molecular breast imaging; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older · Female only
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Arterial Occlusion, Cardiovascular Diseases, Atherosclerosis, Hematoma, Anticoagulant-induced Bleeding, Coronary Artery Disease
Interventions: Statseal with TR Band, TR band only; Device
Lead sponsor: VA Long Beach Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Rotavirus Infections
Interventions: 3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), 7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV), Placebo; Biological · Other
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Coronary Artery Disease
Interventions: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation, Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 82
States / cities: Birmingham, Alabama • Bakersfield, California • La Jolla, California + 67 more

Conditions: Pain, Neoplasm Metastasis, Bone Metastasis of Diverse Origins
Interventions: Cryoablation; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 4 more

Conditions: Wound Healing, Wound Infection
Interventions: Procellera™ Antimicrobial Wound Dressing, ACTICOAT™ Antimicrobial Barrier Dressing, Mepilex® Ag Silver Foam Dressing; Device · Drug
Lead sponsor: Vomaris Innovations; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Oro Valley, Arizona • Tucson, Arizona

Conditions: Breast Tumor
Interventions: RFID Localization, Wire Localization, RFID and Wire Localization; Device
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Dermatitis, Atopic, Eczema
Interventions: Investigational OTC Cream, Cosmetic Eczema Cream, 0.05% Desonide Cream, Placebo Cream; Drug · Other
Lead sponsor: Procter & Gamble Beauty; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: GastroEsophageal Cancer
Interventions: Immune checkpoint inhibitor (ICI) or chemotherapy alone; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mass Lesion
Interventions: Quantitative Transmission Ultrasound; Device
Lead sponsor: QT Ultrasound LLC; Industry
Eligibility: 25 Years and older · Female only
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Rochester, New York

Conditions: Peripheral Arterial Disease
Interventions: Shockwave Lithoplasty® Peripheral Lithoplasty System, Medtronic IN.PACT (DCB); Device · Drug
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 40
States / cities: Little Rock, Arkansas • Palo Alto, California • Aurora, Colorado + 33 more

Conditions: Melanoma
Interventions: Talimogene laherparepvec, GM-CSF; Biological
Lead sponsor: BioVex Limited; Industry
Eligibility: 18 Years and older
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 57
States / cities: Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more

Conditions: White Spot Lesion
Interventions: Pro Seal Sealant, MI Varnish; Device
Lead sponsor: Texas A&M University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Nausea With Vomiting Chemotherapy-Induced
Interventions: Granisetron Transdermal Patch, Intravenous Dexamethasone, Ondansetron; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Cancer
Interventions: Non-contrast DWI, Non-contrast MRI; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 269 participants
Timeline: 2018 – 2029
U.S. locations: 2
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Needle Phobia
Interventions: Lidocaine patch 4%, Placebo Patch, 1% Lidocaine Skin Wheal; Drug · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Fibrous Dysplasia/McCune-Albright Syndrome
Interventions: MRI-based Neuroimaging, Non-contrast MRI, 18F-FDG-PET/CT, 18F-NaF-PET/CT; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 10 Years to 45 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease, Acute Coronary Syndrome, Angina Pectoris
Interventions: Orsiro DES, Xience DES; Device
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 55
States / cities: Fairhope, Alabama • Concord, California • La Mesa, California + 49 more

Conditions: Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Sarcoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions: Computed Tomography with Contrast, Microwave Ablation, Questionnaire Administration, Wedge Excision; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coronary Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases, Chest Pain, Pain, Neurologic Manifestations, Signs and Symptoms, Pathological Conditions, Signs and Symptoms, Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Angina Pectoris
Interventions: Freesolve RMS, Xience DES; Device
Lead sponsor: Teleflex; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,859 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Charleston, West Virginia

Conditions: Smoking
Interventions: Quit smoking, Nicotine patch, Placebo Patch; Behavioral · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lung Cancer
Interventions: Bronchoalveolar Lavage (BAL) during Bronchoscopy; Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Arterial Catheterization
Interventions: Lidocaine/tetracaine patch, Placebo Patch, Subcutaneous injection of 0.5 ml Lidocain 1%, Subcutaneous injection of saline; Drug
Lead sponsor: Medical University of Vienna; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing

Comparing TR Band to Statseal in Conjunction With TR Band II

CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy Adults

TAXUS PERSEUS Workhorse

Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases

Efficacy Study of a Bioelectric Dressing to Treat Wounds Caused by Curettage and Electrodesiccation

Radiofrequency Chip for Localization of Non-Palpable Breast Lesions

Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis

Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)

Non-Inferiority Quantitative Transmission Ultrasound Case Collection Study

Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Comparing Fluoride Varnish and Sealant to Prevent White Spots in Orthodontic Patients

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

Non-contrast DWI for Supplemental Screening

Lidocaine Patch for Epidural Placement Pain in Laboring Women

Pain in Fibrous Dysplasia

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

Neurobiology of Nicotine and Non-nicotine Components of Tobacco Addiction

Investigation of MP Pollution in the Human Respiratory System and Its Relationship to Lung Cancer

Rapydan Topical Anaesthesia for Arterial Cannulation